Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091715 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
A Phase 3 study of Pulmonary Hypertension, sponsored by Actelion.
- Completed
- Registry status
- Phase 3
- Development phase
- 185
- Enrollment target
- 20
- Study locations
NCT00091715: Completed Phase 3 study of Pulmonary Hypertension, sponsored by Actelion.
NCT00091715 is a Phase 3 study of Pulmonary Hypertension that has completed, run by Actelion. The registered enrollment target is 185 participants, below the 611-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00091715, a Phase 3 study of Pulmonary Hypertension, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 185 participants
- Enrollment target
- 20
- Study locations
Study Summary
The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.
Conditions Studied
Interventions
- DRUG placebo
- DRUG bosentan
Study Locations (20)
Other
- The Prince Charles Hospital - Brisbane
- Royal Prince Albert Hospital - Camperdown
- St. Vincent's Hospital - Darlinghurst
- General Hospital of Vienna - Vienna
- UZ Gasthuisberg - Leuven
- Queen Mary Hospital - Hong Kong
- Interni klinika VFN - Prague
- Marseille-Timone - Marseille
Alberta
- University of Calgary - Calgary
- University of Alberta - Edmonton
Ontario
- Victoria Medical Centre - Hamilton
- Toronto General Hospital - Toronto
Alabama
- University of Alabama-Birmingham - Birmingham
California
- Harbor UCLA Medical Center - Torrance
Massachusetts
- Tufts- New England Medical Center - Boston
Michigan
- University of Michigan - Ann Arbor
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2004-04 |
| Est. Completion | 2011-02 |
| Phase | Phase 3 |
What the finished NCT00091715 record still lists
NCT00091715 is an interventional study that assigns participants to a tested intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap, below the 611-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Pulmonary Hypertension appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00091715 names 20 study sites across 11 states, led by Other, Alberta, Ontario.
Frequently Asked Questions
What is clinical trial NCT00091715 about?
NCT00091715 is a clinical study titled "Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II". The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.
What is the current status of trial NCT00091715?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 185 participants. The study started on 2004-04. Estimated completion is 2011-02.
What conditions does trial NCT00091715 study?
This clinical trial studies the following conditions: Pulmonary Hypertension.
What interventions are being tested in trial NCT00091715?
The interventions under investigation include: placebo (DRUG), bosentan (DRUG).
Who is sponsoring clinical trial NCT00091715?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00091715 being conducted?
This trial has 20 study locations across Alabama, California, Massachusetts, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00091715's enrollment target sits among peer trials
185 24th of 72 higher than 49 of 72 other Pulmonary Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
RECRUITING · Phase 3
-
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RECRUITING · Phase 3
-
Safety and Efficacy of FETO in CDH Phase III
RECRUITING · Phase 3
-
Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)
COMPLETED · Phase 3
-
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
COMPLETED · Phase 3
-
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041154 · 185 participants · NA
Behavioral and Neural Representations of Subjective Effort Cost
- NCT04484272 · 185 participants · NA
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
- NCT05020860 · 185 participants · Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- NCT05793541 · 185 participants · NA
Just-in-time Interventions for Reducing Short-term Suicide Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia